Literature DB >> 33725973

Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer: An observational study in Asian patients.

Eun Jung Jung1, Ju-Yeon Kim2, Jae-Myung Kim2, Han Shin Lee1, Seung-Jin Kwag2, Ji-Ho Park2, Taejin Park1, Sang-Ho Jeong1, Chi-Young Jeong2, Young-Tae Ju2, Young-Joon Lee1, Soon-Chang Hong2.   

Abstract

ABSTRACT: This study evaluated the outcomes and prognostic factors for breast cancer according to initial lymph node (LN) status. Among patients with LN-negative breast cancer, we also focused on the prognostic value of estrogen receptor (ER) status.Medical records were retrospectively reviewed for 715 patients who underwent curative surgery for breast cancer between January 2005 and December 2015 at a single Korean institution. We evaluated factors that were associated with metastasis-free survival (MFS) according to LN status.Among the 715 patients (age: 28-87 years), 458 patients (64.1%) did not have axillary LN metastasis. Relative to patients without LN metastasis, patients with LN metastasis had larger tumor sizes and higher histological grades. Among patients with no LN metastasis, ER positivity was associated with non-significantly poorer MFS than ER negativity (mean survival: 138.90 months vs. 146.99 months, p = .17), and patients with LN-negative ER-positive disease had MFS rates of 91.7% at 5 years and 74.5% at 10 years. Among patients with LN-negative ER-positive disease, a poor prognosis was significantly associated with larger tumor size (≥2 cm, P = .03) and older age (≥50 years, P = .03).These results indicate that the risk of metastasis increases over time for patients with LN-negative ER-positive breast cancer, and especially for older patients or patients with larger tumors.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33725973      PMCID: PMC7982180          DOI: 10.1097/MD.0000000000025000

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  28 in total

Review 1.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  Commentary on "aTTom": long-term effects of continuing adjuvant Tamoxifen to 10 years.

Authors:  Hamdy A Azim; Ahmed Saadeldeen
Journal:  Chin Clin Oncol       Date:  2014-03

Review 3.  Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Authors:  Adam M Brufsky; Maura N Dickler
Journal:  Oncologist       Date:  2018-01-19

4.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Authors:  Raimund Jakesz; Richard Greil; Michael Gnant; Marianne Schmid; Werner Kwasny; Ernst Kubista; Brigitte Mlineritsch; Christoph Tausch; Michael Stierer; Friedrich Hofbauer; Karl Renner; Christian Dadak; Ernst Rücklinger; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

Review 5.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

Authors:  R M Elledge; W L McGuire
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

6.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

Authors:  Eleftherios P Mamounas; Jong-Hyeon Jeong; D Lawrence Wickerham; Roy E Smith; Patricia A Ganz; Stephanie R Land; Andrea Eisen; Louis Fehrenbacher; William B Farrar; James N Atkins; Eduardo R Pajon; Victor G Vogel; Joan F Kroener; Laura F Hutchins; André Robidoux; James L Hoehn; James N Ingle; Charles E Geyer; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

7.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

Authors:  Lisa K Dunnwald; Mary Anne Rossing; Christopher I Li
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Authors:  Valentina Cocciolone; Katia Cannita; Maria Letizia Calandrella; Enrico Ricevuto; Paola Lanfiuti Baldi; Tina Sidoni; Azzurra Irelli; Stefania Paradisi; Laura Pizzorno; Valter Resta; Alberto Bafile; Edoardo Alesse; Alessandra Tessitore; Corrado Ficorella
Journal:  Oncotarget       Date:  2017-06-16

Review 9.  Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Authors:  Hanxiao Xu; Shengnan Yu; Qian Liu; Xun Yuan; Sridhar Mani; Richard G Pestell; Kongming Wu
Journal:  J Hematol Oncol       Date:  2017-04-24       Impact factor: 17.388

Review 10.  The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells.

Authors:  Denis G Alferez; Bruno M Simões; Sacha J Howell; Robert B Clarke
Journal:  Curr Stem Cell Rep       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.